Autoimmune Complications of Chronic Lymphocytic Leukemia

Seminars in Oncology

Volumn 33, Issue 2, 2006, Pages 230-239

  Hamblin, Terry J ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AUTOANTIBODY; AZATHIOPRINE; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DANAZOL; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN; PENICILLIN G; PENTOSTATIN; PEPTIDE; PREDNISOLONE; PURINE DERIVATIVE; RANITIDINE; RITUXIMAB; STANOZOLOL; TRANEXAMIC ACID; VACCINE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANEMIA; ANGIONEUROTIC EDEMA; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; AUTOIMMUNITY; BLISTER; CELL FUNCTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; GLOMERULONEPHRITIS; HELPER CELL; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; HYPERTENSION; INFECTION; LYMPHOCYTE FUNCTION; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PEMPHIGOID; PEMPHIGUS; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; SEPSIS; SPLENECTOMY; STOMACH EROSION; T LYMPHOCYTE ACTIVATION; TUMOR CELL; VACCINATION;

AUTOIMMUNE DISEASES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC;

EID: 33646477111     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.01.011     Document Type: Article

References (144)

1. Engelfriet C.P., Overbeeke M.A.M., and von dem Borne A.E.G.K. Autoimmune hemolytic anaemia. Semin Hematol 29 (1992) 3-12
2. Berlin R. Red cell survival studies in normal and leukaemic subjects; latent haemolytic syndrome in leukaemia with splenomegaly-Nature of anaemia in leukaemia-Effect of splenomegaly. Acta Med Scand 139 suppl 252 (1951) 1-141
3. Wasserman L.R., Stats D., Schwartz L., et al. Symptomatic and hemopathic hemolytic anaemia. Am J Med 18 (1955) 961-989
4. Pisciotta A.V., and Hirschboeck J.S. Therapeutic considerations in chronic lymphocytic leukemia. Arch Intern Med 99 (1957) 334-335
5. Beickert A. Die hämolytische Verlausform der chronischen lymphatischen Leukämie. Munch Med Woschenschr 101 (1959) 2067-2072
6. Dameshek W., and Schwartz R.S. Leukemia and auto-immunization. Some possible relationships. Blood 14 (1959) 1151-1158
7. Troup S.B., Swisher S.N., and Young L.E. The anemia of leukemia. Am J Med 28 (1960) 751-763
8. Videbæk A.A. Auto-immune hemolytic anemia in some malignant systemic diseases. Acta Med Scand 171 (1962) 463-476
9. Bergsagel D.E. The chronic leukaemias. A review of disease manifestations and the aims of therapy. Can Med Assoc J 96 (1967) 1615-1620
10. Dighiero G. Hypogammaglobulinemia and disordered immunity in CLL. In: Cheson B. (Ed). Chronic Lymphocytic Leukaemia. Scientific Advances and Clinical Developments (1993), NT, Dekker, New York 167-180
11. Hamblin T.J., Oscier D.G., and Young B.J. Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol 39 (1986) 713-716
12. Minot G.R., and Buckman T.E. The blood platelets in the leukemias. Am J Med Sci 169 (1925) 477-485
13. Harrington W.J., and Arimura G. Immune reactions of platelets. In: Johnson S.A., Monto R.W., Rebuck J.W., et al. (Eds). Blood Platelets (1961), Little Brown, Boston, MA 659-670
14. Ebbe S., Wittels B., and Dameshek W. Autoimmune thrombocytopenic purpura ("ITP type") with chronic lymphocytic leukemia. Blood 19 (1962) 23-27
15. Dührsen U., Augener W., Zwingers T., et al. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders. Analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol 67 (1987) 235-239
16. Loughran T.P., Kardin M.E., Starkebaum G., et al. Leukaemia of large granular lymphocytes. association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anaemia. Ann Intern Med 102 (1986) 169-175
17. + cells in the pathogenesis of neutropenia in patients with B-cell chronic lymphocytic leukaemia. Eur J Haematol 55 (1995) 33-41
18. Lamy T., and Loughran T.P. Current concepts. Large granular lymphocyte leukaemia. Blood Rev 13 (1999) 230-240
19. Lacy M.Q., Kurtin P.J., and Tefferi A. Pure red cell aplasia. Association with large granular lymphocytic leukaemia and the prognostic value of cytogenetic abnormalities. Blood 87 (1996) 3000-3006
20. Chikkappa G., Zarrabi M.H., and Tsan M.F. Pure red cell aplasia in patients with chronic lymphocytic leukaemia. Medicine (Baltimore) 65 (1986) 339-351
21. Diehl L.F., and Ketchum L.H. Autoimmune disease and chronic lymphocytic leukaemia. Autoimmune hemolytic anaemia, pure red cell aplasia and autoimmune thrombocytopenia. Semin Hematol 25 (1998) 80-97
22. Lehner-Netsch G., Barry A., and Delage J.M. Leukemias and autoimmune diseases. Sjøgren's syndrome and hemolytic anemia associated with chronic lymphocytic anemia. Can Med Assoc J 100 (1969) 1151-1154
23. Dathan J.R.E., Heyworth M.F., and MacIver A.G. Nephtotic syndrome in chronic lymphocytic leukaemia. Br Med J 3 (1974) 655-657
24. Cuni L.J., Grünwald H., and Rosner F. Bullous pemphigoid in chronic lymphocytic leukemia with the demonstration of anti-basement membrane antibodies. Am J Med 57 (1974) 987-992
25. Haubenstock A., and Zalusky R. Autoimmune hyperthyroidism and thrombocytopenia in a patient with chronic lymphocytic leukemia. Am J Hematol 19 (1985) 281-283
26. Miller D.G. Patterns of immunological deficiency in lymphomas and leukemias. Ann Intern Med 57 (1962) 703-715
27. Dameshek W. Chronic lymphocytic leukemia-An accumulative disease of immunologically incompetent lymphocytes. Blood 24 (1967) 566-584
28. Sokol R.J., Hewitt S., Booker D.J., et al. An enzyme-linked direct antiglobulin test for assessing erythrocyte bound immunoglobulins. J Immunol Methods 106 (1988) 31-35
29. Mauro F.R., Foa R., Cerretti R., et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia. Clinical, therapeutic, and prognostic features. Blood 95 (2000) 2786-2792
30. Stevenson F.K., Hamblin T.J., Stevenson G.T., et al. Extracellular idiotypic immunoglobulin arising from human leukaemia B lymphocytes. J Exp Med 152 (1980) 1484-1496
31. Broker B.M., Klajman A., Youinou P., et al. Chronic lymphocytic leukemis (CLL) cells secrete multispecific autoantibodies. J Autoimmune 1 (1988) 469-481
32. Sthoeger Z.M., Wakai M., Tse D.B., et al. Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med 169 (1989) 255-268
33. Beaume A., Brizard A., Dreyfus B., et al. High incidence of serum monoclonal Igs detected by a sensitive immunoblotting technique in B-cell chronic lymphocytic leukemia. Blood 84 (1994) 1216-1219
34. Manohar V., Brown E., Leiserson W.M., et al. Expression of Ly-1 by a subset of B lymphocytes. J Immunol 129 (1982) 532-538
35. Hayakawa K., Hardy R.R., Parks D.R., et al. The Ly-1 B cell subpopulation in normal, immunodefective and autoimmune mice. J Exp Med 157 (1983) 202-218
36. Herzenberg L.A., Stall A.M., Lalor P.A., et al. The Ly1-B cell lineage. Immunol Rev 93 (1986) 81-102
37. Hayakawa K., Hardy R.R., and Herzenberg L.A. Peritoneal Ly1-B cells. Genetic control, autoantibody production, increased lambda light chain expression. Euro J Immunol 16 (1986) 450-456
38. Dighiero G. Relevance of murine models in elucidating the origin of B-CLL lymphocytes and related immune associated phenomena. Semin Hematol 24 (1987) 240-251
39. Dighiero G., Poncet P., Rouyre S., et al. Newborn Xid mice carry the genetic information for the production of natural autoantibodies. J Immunol 136 (1986) 4000-4005
40. Miller R.A., and Gralow J. The induction of Leu-1 antigen expression in human malignant and normal B cells by phorbolmyristic acetate (PMA). J Immunol 133 (1984) 3408-3412
41. Holmberg D., Forsgren S., Ivars F., et al. Reactions among IgM antibodies derived from normal neonatal mice. Eur J Immunol 14 (1984) 435-440
42. Lymberi P., Dighiero G., Ternyck T., et al. A high incidence of cross reactive idiotypes among murine natural autoantibodies. Eur J Immunol 5 (1985) 702-707
43. Kearney J.F., and Vakil M. Idiotype directed interactions during ontogeny play a major role in the establishment of the adult B cell repertoire. Immunol Rev 94 (1986) 39-62
44. Dighiero G., Hart S., Lim A., et al. Autoantibody activity of immunoglobulins isolated from B cell follicular lymphomas. Blood 78 (1981) 581-585
45. Sikora K., Kirkorian J., and Levy R. Monoclonal immunoglobulin rescued from a patient with chronic lymphocytic leukemia and AIHA. Blood 54 (1979) 513-518
46. Sthoeger Z.M., Stoeger D., Shtalrid M., et al. Mechanism of AIHA in chronic lymphocytic leukemia. Am J Hematol 43 (1993) 259-264
47. H4-21 gene segment is responsible for the major cross-reactive idiotype. J Immunol 146 (1991) 4385-4391
48. Pascual V., Victor K., Spellerberg M., et al. VH restriction among human cold agglutinins. The VH4-21 gene segment is required to encode anti-I and anti-i specificities. J Immunol 149 (1992) 2337-2344
49. Crisp D., and Pruzanski W. B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins). Am J Med 72 (1982) 915-922
50. Ruzickova S., Pruss A., Odendahl M., et al. Chronic lymphocytic leukemia preceded by cold agglutinin disease. Intraclonal immunoglobulin light chain diversity in V(H)4-34 expressing single leukemic cells. Blood 100 (2002) 3419-3422
51. Zaja F., Vianelli N., Sperotto A., et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 44 (2003) 1951-1955
52. He S., Tsang S., North J., et al. Epitope mapping of C1 inhibitor autoantibodies from patients with acquired C1 inhibitor deficiency. J Immunol 156 (1996) 2009-2013
53. Chevailler A., Arlaud G., Ponard D., et al. C-1-inhibitor binding monoclonal immunoglobulins in three patients with acquired angioneurotic edema. J Allergy Clin Immunol 97 (1996) 998-1008
54. Lewis F.B., Schwarz R.S., and Damashek W. X-irradiation and alkylating agents as possible trigger mechanisms in autoimmune complications of malignant lymphoproliferative diseases. Clin Exp Immunol 1 (1966) 3-11
55. Catovsky D., and Foa R. B-cell chronic lymphocytic leukaemia. In: Catovsky D., and Foa R. (Eds). The Lymphoid Leukaemias (1990), Butterworths, London, UK 73-112
56. Thompson-Moya L., Martin T., Heuft H.G., et al. Allergic reaction with immune hemolytic anaemia arising from chlorambucil. Am J Hematol 32 (1989) 230-231
57. Hansen M.M. Chronic lymphocytic leukaemia. Clinical studies based on 189 cases followed for a long time. Scand J Haematol 18 suppl 1 (1973) 1-282
58. Myint H., Copplestone J.A., Orchard J., et al. Fludarabine-related AIHA in patients with chronic lymphocytic leukaemia. Br J Haematol 91 (1995) 341-344
59. Bastion Y., Coiffier B., Dumontet C., et al. Severe AIHA in two patients treated with fludarabine for chronic lymphocytic leukemia. Ann Oncol 3 (1992) 171-172
60. Di Raimondo F., Guistolisi R., Cacciola E., et al. AIHA in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma 11 (1993) 63-68
61. Weiss R.B., Freiman J., Kweder S.L., et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 16 (1998) 1885-1889
62. Hamblin T.J. Autoimmune disease and its management in chronic lymphocytic leukaemia. In: Cheson B.D. (Ed). Chronic Lymphoid Leukemias (ed 2) (2001), Dekker, New York, NY 435-458
63. Montillo M., Tedeschi A., and Leoni P. Recurrence of autoimmune thrombocytopenia after treatment with fludarabine in a patient with chronic lymphocytic leukaemia. Leuk Lymphoma 15 (1994) 187-188
64. Stern S.C., Shah S., and Costello C. Probable autoimmune neutropenia induced by fludarabine treatment for chronic lymphocytic leukaemia. Br J Haematol 106 (1999) 836-837
65. Antich Rojas J., Balaguer H., and Cladera A. Selective aplasia of the red-cell series after fludarabine administration in a patient with chronic B-cell lymphatic leukaemia. Sangre (Barcelona) 42 (1997) 254-256
66. Leporier M., Reman O., and Troussard X. Pure red cell aplasia with fludarabine for chronic lymphocytic leukaemia. Lancet 342 (1993) 555
67. Byrd J.C., Hertler A.A., Weiss R.B., et al. Fatal recurrence of autoimmune hemolytic anaemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anaemia. Ann Oncol 6 (1995) 300-301
68. Robak T., Blasinska-Morawiec M., Krykowski E., et al. Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine (cladribine). Eur J Haematol 58 (1997) 109-113
69. Hamblin T.J., Orchard J.A., Myint H., et al. Fludarabine and hemolytic anaemia in chronic lymphocytic leukaemia. J Clin Oncol 16 (1998) 3209
70. Fleischman R.A., and Croy D. Acute onset of severe autoimmune hemolytic anaemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukaemia. Am J Hematol 48 (1995) 293
71. Chasty R.C., Myint H., Oscier D.G., et al. Autoimmune haemolysis in patients with B-CLL treated with chlorodeoxyadenosine (CDA). Leukemia Lymphoma 29 (1998) 391-398
72. Otton S.H., Turner D.L., Frewin R., et al. Autoimmune thrombocytopenia after treatment with Campath 1H in a patient with chronic lymphocytic leukaemia. Br J Haematol 106 (1999) 261-262
73. Orchard J., Bolam S., Myint H., et al. In patients with lymphoid tumours recovering from the autoimmune complications of fludarabine, relapse may be triggered by conventional chemotherapy. Br J Haematol 102 (1998) 1112-1113
74. Eichhorst B.F., Busch R., Hopfinger G., et al. Fludarabine plus cyclophosphamide (FC) is superior to fludarabine (F) alone in first line therapy of chronic lymphocytic leukemia (CLL). Results of a phase III study of the German CLL study group (GCLLSG) Haematologica 90 (2005) 144 suppl, abstr 0366
75. Catovsky D., Richards S., and Hillman P. Early results from LRF CLL4. A UK multicenter randomized trial. Blood 106 (2005) 212a suppl, abstr
76. Bazarbachi A., Bachelez H., Dehen L., et al. Lethal paraneoplastic pemphigus following treatment of chronic lymphocytic leukaemia with fludarabine. Ann Oncol 6 (1995) 730-731
77. Braess J., Reich K., Willert S., et al. Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin's lymphoma of B-cell type (B-NHL). Ann Hematol 75 (1997) 227-230
78. Gooplu C., Littlewood T.J., Frith P., et al. Paraneoplastic pemphigus-An association with fludarabine. Br J Dermatol 144 (2001) 1102-1104
79. Oppenheim M. Verhandlungen Der Weiner Dermatologischen Gesellschaft. Arch Dermatol Syphiligr 101 (1910) 379-382
80. Sachs O. Ueber Pemphigoide Hauteruption in Einem Falle von Lymphatischer Leukaemie. Wien Klin Wochenschr 34 (1921) 317
81. Laskaris G.C., Papavasilou S.S., Bovopoulou O.D., et al. Association of oral pemphigus with chronic lymphocytic leukemia. Oral Surg Oral Med Oral Pathol 50 (1980) 244-249
82. Goodnough L.T., and Muir A. Bullous pemphigoid as a manifestation of chronic lymphocytic leukaemia. Arch Intern Med 140 (1980) 1526-1527
83. Anhalt G.J., Kim S.C., Stanley J.R., et al., Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 323 (1990) 1729-1735
84. Fried R., Lynfield Y., Vitale P., et al. Paraneoplastic pemphigus appearing as a bullous pemphigoid eruption after palliative radiation therapy. J Am Acad Dermatol 29 (1993) 815-817
85. Lee M.S., Kossard S., Ho K.K., et al. Paraneoplastic pemphigus triggered by radiotherapy. Aust J Dermatol 36 (1995) 206-210
86. Macheta M.P., Parapia L.A., and Gouldesbrough D.R. Renal failure in a patient with chronic lymphocytic leukaemia treated with fludarabine. J Clin Pathol 48 (1995) 181-182
87. Tisler A., Pierratos A., and Lipton J.H. Crescentic glomerulonephritis with p-ANCA positivity in fludarabine-treated chronic lymphocytic leukaemia. Nephrol Dial Transplant 11 (1996) 2306-2308
88. Boldt D.H., Van Hoff D.D., Kuhn J.G., et al. Effect on human peripheral lymphocytes of the in vivo administration of 9-β-D-arabinofuranosyl-5′-monophosphate (NSC312887) a new purine antimetabolite. Cancer Res 44 (1984) 4661-4666
89. Rosenkrantz K., Dupont B., and Flomenberg N. Relevance of autocytotoxic and autoregulatory lymphocytes in the maintenance of self tolerance. Concepts Immunopathol 4 (1987) 22-41
90. Shevach E.M., Thornton A., and Suri-Payer E. T lymphocyte-mediated control of autoimmunity. Novartis Found Symp 215 (1998) 200-211
91. + naturally anergic and suppressive T cells. Induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 19 (1998) 1969-1980
92. + immunoregulatory T cells suppress polyclonal T cell activation by inhibiting interleukin 2 production. J Exp Med 188 (1998) 287-296
93. Winberg K., and Parkman R. Age, the thymus and T lymphocytes. N Engl J Med 332 (1995) 182-183
94. Peller S., and Kaufman S. Decreased CD45RA T cells in B-cell chronic lymphatic leukaemia patients. Correlation with disease stage. Blood 78 (1991) 1569-1573
95. Serreze D.V., Fleming S.A., Chapman H.D., et al. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol 161 (1998) 3912-3918
96. Dazzi F., D'Andrea E., Biasi G., et al. Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens. Clin Immunol Immunopathol 75 (1995) 26-32
97. Barker R.N., Hall A.M., Standen G.R., et al. Identification of T-cell epitopes on the Rhesus polypeptides in autoimmune hemolytic anemia. Blood 90 (1997) 62701-62715
98. Hall A.M., Vickers M.A., McLeod E., et al. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood 105 (2005) 2007-2015
99. Barcellini W., Montesano R., Clerici G., et al. In vitro production of anti-RBC antibodies and cytokines in chronic lymphocytic leukemia. Am J Hematol 71 (2002) 177-183
100. Efremov D.G., Ivanovski M., Siljanovski N., et al. Restricted immunoglobulin VH region repertoire in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia. Blood 87 (1996) 3869-3876
101. Hamblin T., Davies Z., Oscier D., et al. In chronic lymphocytic leukaemia (CLL) autoimmune haemolytic anaemia (AIHA) is not related to any particular immunoglobulin V gene usage. Br J Haematol 105 suppl 1 (1999) 88
102. H 1-69 (51p1) genes. Blood 90 (1997) 209b suppl 1, abstr 3672
103. Tobin G., Thunberg U., Karlsson K., et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 104 (2004) 2879-2885
104. Ghiotto F., Fais F., Valetto A., et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest 113 (2004) 1008-1016
105. Messmer B.T., Albesiano E., Efremov D.G., et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 200 (2004) 519-525
106. Lehman P.V., Forsthuber T., Miller A., et al. Spreading of T cell autoimmunity to cryptic determinants of an autoantigen. Nature 358 (1992) 155-157
107. Hall A.M., Ward F.J., Vickers M.A., et al. Interleukin-10-mediated regulatory T-cell responses to epitopes on a human red blood cell autoantigen. Blood 100 (2002) 4529-4536
108. Dameshek W., and Komninos Z.P. The present status of treatment of autoimmune hemolytic anemia with ACTH and cortisone. Blood 11 (1956) 648-664
109. Collins P.W., and Newland A.C. Treatment modalities of autoimmune blood disorders. Semin Hematol 29 (1992) 64-74
110. Byrd J.C., Hertler A.A., Weiss R.B., et al. Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia. Ann Oncol 6 (1995) 300-301
111. Hamblin T.J., Orchard J.A., Myint H., et al. Fludarabine and hemolytic anemia in chronic lumphocytic leukemia. J Clin Oncol 16 (1998) 3209-3210
112. Coon W.W. Splenectomy in the treatment of hemolytic anemia. Arch Surg 120 (1985) 625-6281
113. Dacie J.V. Autoimmune hemolytic anemia. Arch Intern Med 135 (1975) 1293-1300
114. Ruchlemer R., Wotherspoon A.C., et al. Splenectomy in mantle cell lymphoma with leukaemia. A comparison with chronic lymphocytic leukaemia. Br J Haematol 118 (2002) 952-958
115. Hill J., Walsh R.M., McHam S., et al. Laparoscopic splenectomy for autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia. A case series and review of the literature. Am J Hematol 75 (2004) 134-138
116. Jurlander J., de Nully Brown P., Skov P.S., et al. Improved vaccination response during ranitidine treatment, and increased plasma histamine concentrations, in patients with B cell chronic lymphocytic leukemia. Leukemia 9 (1995) 1902-1909
117. Flores G., Cunningham-Rundles C., Newland A.C., et al. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia. results in 73 patients. Am J Hematol 44 (1993) 237-242
118. Ruess-Borst M.A., Waller H.D., and Muller C.A. Successful treatemnt of steroid resistant hemolysis in chronic lymphocytic leukemia with cyclosporine A. Am J Hematol 9 (1994) 357-359
119. Cortes J., O'Brien S., Loscertales J., et al. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer 92 (2001) 2016-2022
120. Seipelt G., Bohme A., Koschmieder S., et al. Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome. Ann Hematol 80 (2001) 170-173
121. Cabrera J., Peñalver F.J., Millan I., et al. Mabthera (Rituximab) in the treatment of 92 patients with refractory immune thrombocytopenic purpura. Blood 104 (2004) 571a abstr 2074
122. Tokunaga M., Fujii K., Saito K., et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology 44 (2005) 176-182
123. Stasi R., Brunetti M., Stipa E., et al. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 103 (2004) 4424-4428
124. Dupuy A., Viguier M., Bedane C., et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-cd20 monoclonal antibody). Arch Dermatol 140 (2004) 91-96
125. Shaw T., Quan J., and Totoritis M.C. B cell therapy for rheumatoid arthritis. The rituximab (anti-CD20) experience. Ann Rheum Dis 62 (2003) 55-59
126. Sansonno D., De Re V., Lauletta G., et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101 (2003) 3818-3826
127. Fischer K.-G., Deschler B., Lubbert M., et al. Acquired high-titer factor VIII inhibitor. fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmapheresis. Blood 101 (2003) 3753-3754
128. Pestronk A., Florence J., Miller T., et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 74 (2003) 485-489
129. Engelhardt M., Jakob A., Ruter B., et al. Severe cold hemagglutinin disease (CHD) successfully treated with rituximab. Blood 100 (2002) 1922-1923
130. Gupta N., Kavuru S., Patel D., et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 16 (2002) 2092-2095
131. Zaja F., Vianelli N., Sperotto A., et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 44 (2003) 1951-1955
132. Hegde U.P., Wilson W.H., White T., et al. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 100 (2002) 2260-2262
133. Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood 99 (2002) 1092-1094
134. Chemnitz J., Draube A., Diehl V., et al. Successful treatment of steroid and cyclophosphamide-resistant hemolysis in chronic lymphocytic leukemia with rituximab. Am J Hematol 69 (2002) 232-233
135. Heizmann M., Itin P., Wernli M., et al. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab. Report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 66 (2001) 142-144
136. Guinet M.J., Liew K.H., Quong G.G., et al. A study of splenic irradiation in chronic lymphocytic leukemia. Int J Radiat Oncol Biol Phys 16 (1989) 225-229
137. Esa E.C., Ray P.K., Swami V.K., et al. Specific immunoadsorption of IgG antibody in a patient with chronic lymphocytic leukemia and autoimmune hemolytic anemia. Am J Med 71 (1981) 1035-1040
138. Vesely S.K., Perdue J.J., Rizvi M.A., et al. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy. A systematic review. Ann Intern Med 140 (2004) 112-120
139. Ahn Y.S., Harrington W.J., Mylvagnam R., et al. Slow infusion of vinca alkaloids in the treatment of idiopathic thrombocytopenic purpura. Ann Intern Med 100 (1984) 192-196
140. Pott-Hoeck C., and Hiddemann W. Purine analogues in the treatment of low grade lymphomas and chronic lymphocytic leukemias. Ann Hematol 6 (1995) 421-433
141. Meir F., Sonnichsen K., Schaumburg-Lever G., et al. Epidermolysis bullosa acquisita. Efficiency of high dose intravenous immunoglobulins. J Am Acad Dermatol 29 (1993) 334-337
142. Mohr C., Sunderkottewr C., Hildebrand A., et al. Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins. Br J Dermatol 132 (1995) 824-826
143. Marcovic S.N., Inwards D.J., Frigas E.A., et al. Acquired C1 esterase inhibitor deficiency. Ann Intern Med 132 (2000) 144-150
144. Keating M.J., O'Brien S., Albitar M., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 4079-4088